Affiliation:
1. Bosiyan Biotechnology (Suzhou) Co., Ltd.
Abstract
Abstract
Background
In natural physiological conditions, FGF is a pleiotropic growth factor with multiple bio-activities and FGF/FGFR system has many important biological functions and roles. Interestingly, more and more evidences show that FGF/FGFR system plays an important role in the occurrence and development of pancreatic ductal adenocarcinoma.
Methods
In our study, we explored the cellular characteristics of FGF/FGFR system in pancreatic ductal adenocarcinoma cells. In addition, we also investigated the relationship between nuclear localized FGF/FGFR and cisplatin resistance. A series of experimental techniques including indirect immunofluorescence, Western-blot and ELISA were used to analyze the cellular characteristics of FGF/FGFR. We systematically assessed the cell behavior of IGF-1/IGF-1R in the Pancreatic ductal adenocarcinoma cell model.
Results
We have three main findings: First, we found that IGF-1R could transport into the cell nuclei of Pancreatic ductal carcinoma cell, and the nuclear-localized FGF/FGFR was closely related to the proliferation of Pancreatic ductal carcinoma cells. Additionally, we also found that the nuclear-localized FGF/FGFR might be closely associated with cisplatin resistance in pancreatic ductal adenocarcinoma, this may be a potential mechanism of cisplatin resistance; Secondly, we found that the nuclear-localized FGF/FGFR showed a positive correlation with the intensity of AKT signaling.
Conclusions
Taken together, this work lays the foundation for further research on the relationship between the nuclear FGF/FGFR and the pancreatic ductal adenocarcinoma development or cisplatin resistance in pancreatic ductal adenocarcinoma.
Publisher
Research Square Platform LLC
Reference29 articles.
1. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives;Wang S;Signal Transduct Target Ther,2021
2. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ducreux M;Ann Oncol,2015
3. Cancer statistics, 2019;Siegel RL;CA Cancer J Clin.,2019
4. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma;Kopp JL;Cancer Cell.,2012
5. Sarvepalli D, Rashid MU, Rahman AU, Ullah W, Hussain I, Hasan B, Jehanzeb S, Khan AK, Jain AG, Khetpal N et al. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer. Crit Rev Oncog. 2019, 24:199–212.